According to Michael Steinberg in Seeking Alpha:
The FDA is not looking favorably on me-too drugs.
The FDA is requiring “outcomes” based clinical testing, with exceptions only for critical need.
Foreign countries are not allowing patent extensions for minor product life cycle changes.
No comments:
Post a Comment